Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daxdilimab for moderate-to-severe primary discoid lupus erythematosus
2023-509746-35-00Phase 2Completed
- Sponsor
- Horizon Therapeutics
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial in discoid lupus erythematosus (DLE) comparing Daxdilimab with Placebo (2 arms). Primary endpoint: Mean change in CLASI-A score from baseline to Week 24. Started May 2024; status: completed.
02
Drugs
daxdilimab
03
Conditions
discoid lupus erythematosus (DLE)
Beyond the preview
Go deeper on 2023-509746-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509746-35-00.